Skip to main content
. 2009 Feb;1(1):13–26. doi: 10.1177/1759720X09343221

Figure 2.

Figure 2.

Study design of the denosumab phase 2 study in postmenopausal women with low bone mineral density showing reallocation of groups. Reprinted from [Miller et al. 2008] with permission from Elsevier. Q3M, every 3 months; Q6M, every 6 months.